Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.51 |
| ▸ | RXRB | P28702 | 9/20 | 0.51 |
| ▸ | RXRG | P48443 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30139917 | 0.81 | ALDH1A1 (0.53) | RXRARXRBRXRGNPC1RAB9A | |
| SCHEMBL15631232 | 0.80 | RAB9A (0.69) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| SCHEMBL678711 | 0.79 | MAPT (0.57) | NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL15632431 | 0.78 | ALDH1A1 (0.50) | RXRARXRBRXRGNPC1RAB9A | |
| SCHEMBL15081032 | 0.77 | L3MBTL1 (0.41) | RXRARXRBNPC1RAB9AALDH1A1 | |
| SCHEMBL2755830 | 0.77 | L3MBTL1 (0.50) | NPC1RAB9AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL12142769 | 0.77 | SLC7A5 (0.60) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL12142657 | 0.77 | SLC7A5 (0.60) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL100476 | 0.76 | ALDH1A1 (0.68) | RXRARXRBRXRGNPC1RAB9A | |
| SCHEMBL16202052 | 0.76 | SMN1; SMN2 (0.47) | NPC1RAB9AALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9527866-B2 | Processes for production of intermediates for 2-alkyl cephem compounds | SHIONOGI & CO., LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9334289-B2 | Cephem compound having catechol or pseudo-catechol structure | SHIONOGI & CO., LTD. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9242999-B2 | Cephem compound having pyridinium group | SHIONOGI & CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20150344502-A1 | CEPHEM COMPOUND | SHIONOGI & CO., LTD. (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150291619-A1 | PROCESSES FOR PRODUCTION OF INTERMEDIATES FOR 2-ALKYL CEPHEM COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20140114060-A1 | CEPHEM COMPOUND HAVING PYRIDINIUM GROUP | SHIONOGI & CO., LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | SHIONOGI & CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | COMT, CMBL, CEP170 | RXRA 4877/4885RXRB 4860/4885RXRG 4862/4885 |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | RXRA 4848/4885RXRB 4852/4885RXRG 4823/4885 |
| US-20140114060-A1 | CEPHEM COMPOUND HAVING PYRIDINIUM GROUP | CEP170, PEPD, CMBL | RXRA 4814/4885RXRB 4723/4885RXRG 4769/4885 |
| US-20150291619-A1 | PROCESSES FOR PRODUCTION OF INTERMEDIATES FOR 2-ALKYL CEPHEM COMPOUNDS | SQOR, DHPS, NISCH | RXRA 4677/4885RXRB 4679/4885RXRG 4736/4885 |
| US-20150344502-A1 | CEPHEM COMPOUND | PRMT6, CEP170, NR0B1 | RXRA 1812/4885RXRB 1414/4885RXRG 2177/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | RXRA 4879/4885RXRB 4881/4885RXRG 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.